Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...
Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...
Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback